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Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of the
motor neuron, which selectively affects it both at central (ﬁrst motor-neuron) and peripheral level
(second motor-neuron). The disease shows up at a mean age of 56 years and the most affected are
males. Although ALS may start as a bulbar or spinal disease, with the progression of the disease
typically both become evident. Pharmacological approved treatments for ALS are still limited and
include riluzole and edaravone which improve survival over time. Despite this, ALS leads to
progressive muscle involvement and requires a complex multidisciplinary approach to manage
increasing disability which goes beyond motor neurons. Sialorrhea is, amongst others, one of the
most disabling symptoms inALS.The complexity inmanaging saliva is due to amuscular spasticity
and to a scarce palatino-lingual muscles control, rather than to an overproduction of saliva. These
features could increase the risk of aspiration pneumonia and limit the use of noninvasivemechanical
ventilation. We reviewed the treatment for sialorrhea in ALS patients that are available at this time,
emphasizing pros and cons for each approach. Our purpose is to create a practical tool for the
diagnosis, in order to facilitate the quantiﬁcation and management of sialorrhea in everyday
practice.
Keywords: amyotrophic lateral sclerosis, sialorrhea, botulinum toxin, radiotherapy salivary
gland, anticholinergic drug
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of
the motoneurone, which selectively affects the motor neurons, both at central (ﬁrst
moto-neuron) and peripheral level (second motor neuron). Its prevalence is around
4–6 people per 100,000 population .1 The disease begins at a mean age of 56 years
and the most affected are males.2 ALS may begin as a bulbar or spinal disease but
as with the progression of the disease, typically both become evident. The bulbar
onset forms have a median survival of 20 months while a relatively longer survival
is described for the spinal onset forms (29 months).1
Pharmacological approved treatments for ALS are still limited and include
riluzole and edaravone which improve survival over time.2 Despite this, ALS
leads to progressive muscle involvement and requires a complex multidisciplinary
approach to manage increasing disability which goes beyond motor neurons.
Sialorrhea is amongst others, one of the most disabling symptoms in ALS.3 This
is particularly relevant in patients with bulbar palsy experience in whom sialorrhea
is associated with mucous secretions and saliva along with an impairment of ability
to swallow secretions but not due to an increasing of saliva production: this
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pathological alteration is caused by tongue spasticity, oro-
facial and palatino-lingual muscle control failure, facial
muscular weakness, as well as to an inability to maintain
oral and buccal competence.3,4
Major salivary glands producing saliva are three: parotid,
submandibular and sublingual (Figure 1).
Moreover, there are several minor salivary glands diffused
in the oral cavity. Saliva is mainly made up of water, electro-
lytes, proteins and enzymes. From the production to the secre-
tive phase through the reabsorption of electrolytes, saliva is
subjected to signiﬁcant modiﬁcations. It changes from being
isotonic in glandular acini to hypotonic in the glands ductal
system. Salivar proteins are constantly produced and stored
inside cellular granules; electrolytic secretion is mainly sup-
ported by parasimpatic stimulation, while protein secretion is
activated by simpatic stimulation. However, there is an inter-
action between the two regulatory systems. Under stimulation,
the main production of saliva comes from the parotid glands
(66% of the total ﬂow) and around 1.0–1.5 L of saliva are
secreted everyday by a healthy person and this quantity con-
sists inwater, electrolytes, antimicrobials, enzymes and growth
factors.5 The main functions of saliva are to facilitate mastica-
tion, deglutition and the beginning of digestion. Furthermore,
saliva performs an important role in the protection of the oral
mucosa and of the teeth.
The innervation of salivary glands is mainly constituted
by parasympathetic nerves. The submandibular glands are
the major responsibilities for the production of unstimulated
saliva. This gland is a mixed but mostly serous gland,
whereas the parotid gland, a purely serous gland, secretes
saliva mainly during chewing. The sublingual gland is
purely mucous.5
Fifty percent of ALS patients is affected by impairment
to control saliva production during the course of the dis-
ease, and nearly a quarter of patients develop moderate-to-
severe symptoms.6 Progressive sialorrhea and drooling can
cause skin maceration, soaking of clothes and exacerbation
of dysarthria. These patients could develop psychological
stress and social embarrassment, decreasing quality of life.
The risk of aspiration pneumonia is increased by the pre-
sence of secretions in the throat and bronchial tree and by
the inability of the patient to perform an effective cough
because of the respiratory muscle weakness.7 In ALS
patients, pulmonary aspiration syndromes are often under-
diagnosed, but they are associated with a high mortality
rate.8 In a cohort of 40 consecutive patients with ALS, six
aspiration pneumonia events were reported in ﬁve cases
(13%).9 A study showed that the cause of death in 41% of
cases was attributable to bronchopneumonia and in 11%
aspiration pneumonia.10 In an analysis of 200 ALS
Patients, the most frequent cause of death was a respira-
tory failure (61%) and the second was pneumonia
(9,6%).11 In an Italian study based on discharge diagnosis,
the incidence of aspiration pneumonia varied from 1 to
2,1%.12 Tolerance to noninvasive ventilation (NIV) is
limited by excessive mucous and drooling and NIV is
important for the management of ALS patients because
an important increase of life expectancy and quality of life
has been shown.13–21
There are substantial differences between the treatment
of bronchial secretions and the serious secretion of sali-
vary glands.
In 2001, the American Academy of Neurology recom-
mended both pharmacologic interventions and non-phar-
macologic approaches of sialorrhea in ALS patients.22 In
2011, a Cochrane review on the treatment for sialorrhea in
people with motor neuron disease and ALS identiﬁed only
one randomized controlled trial.23 The Authors’ conclu-
sions stated that the use of botulinum toxin injections to
salivary glands may be of beneﬁt for the treatment of
sialorrhea in MND. Yet emphasis was placed on the fact
that more information and further research are needed.
There are many reviews in the Cochrane Library which
analyze the effectiveness of symptomatic treatment thera-
pies for ALS patients.24 We reviewed treatments for
Sublingual
gland
Submandibular
gland
Parotid
gland
Figure 1 Anatomy of salivary glands.
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sialorrhea in ALS that are available at this time for ALS
emphasizing pros and cons for each approach with the
purpose of creating a facilitating practical tool to the
diagnosis, quantiﬁcation and management of sialorrhea in
everyday practice.
Measurement of sialorrhea in ALS
In order for clinicians and patients to appreciate the effec-
tiveness of treatment, there needs to be a measurable tool
that will be sensitive to changes. Currently, not many
scales for the assessment of sialorrhea and particularly in
ALS patients have been identiﬁed.
1. In the revised Amyotrophic Lateral Sclerosis
Functional Rating Scale, a validated questionnaire
to monitor disease progression in ALS, three items
assessing the function of bulbar muscles, including
one evaluating sialorrhea, have been inserted.25
2. The Oral Secretion Scale (OSS) has been speciﬁ-
cally designed for the evaluation of hypersialorrhea
in ALS.26,27 The OSS is not designed to evaluate
the effectiveness of invasive treatments for
hypersialorrhea.28
3. The Sialorrhea Scoring Scale: although it has been
developed for Parkinson disease, it was used for
ALS patients. It does not predict tolerance to
NIV.28 These scores should be used before and
after the therapy at least at a reasonable time to
evaluate the effective therapeutic efﬁcacy (at least
two weeks for botulism)
Treatment options
Anticholinergic drugs
Few clinical studies were published about the effectiveness
of these drugs on patients with ALS.29 There are ﬁve
anticholinergic drugs usually used to manage sialorrhea
problems in ALS patients: hyoscine hydrobromide/scopo-
lamine (transdermal patch or oral preparation), oral ami-
triptyline, atropine (sublingual drops, transdermal patch, or
tablets), oral propantheline and oral glycopyrronium bro-
mide/glycopyrrolate.
Regarding dosage, this usually needs to be tailored for
each patient, either because an initial dose may not provide
sufﬁcient symptomatic improvement or because there may
be a need to reduce side effects. The selection of the best
medication often depends upon the severity and frequency
of the drooling and on the severity of dysphagia. In severe
cases, the sublingual or transdermal form is clearly
preferred. Of note, not all oral medications can be given
through a PEG tube because of precipitation or inadequate
absorption if ground. Data from the national ALS Patient
CARE database indicate that over half of ALS patients
responded to treatment with atropine, glycopyrrolate or
amitriptyline.22 In a group of patients affected by chronic
neurological diseases and drooling, discontinuation rate
for scopolamine patches occurred in 13% of patients.
The oral administration of these drugs is more often dis-
continued due to systemic side effects (eg, sedation and
delirium), common in elderly patients rather than because
these drugs are ineffective. Another side effect of these
drugs is the possible thickening of mucous secretions in
the throat and lungs, which is a severe complication, by far
worse than drooling.30 An alternative to oral administra-
tion is the transdermal application. A recent study demon-
strated that scopolamine patches are effective for the
management of sialorrhea in 85% of the treated subjects.7
However, monotherapy was insufﬁcient and about half of
these subjects also required additional therapies 20% had
to discontinue scopolamine patches, mostly because of
skin reaction. Cutaneous reactions, pupillary abnormality
and urinary retention are minor common adverse effects of
scopolamine delivered by skin patches. The administration
of subcutaneous glycopyrrolate (600 g over 12 hrs via a
syringe driver) was reported anecdotally as beneﬁcial in
one patient with bulbar onset in whom traditional drugs
had been ineffective with minimal side effects, also per-
mitting the use of NIV at night.27
Anticholinergic drugs are not effective in more of 30%
of the treated patients. In the long term, these medications
are often not a sustainable therapy for sialorrhea in a great
number of patients.31 Moreover, given the mean age of
onset of ALS patients, there may be comorbidities like
heart diseases, glaucoma, pyloric stenosis, prostatic hyper-
trophy and hepatic and/or renal insufﬁciency where the use
of anticholinergic drugs is contraindicated.
At this time, anticholinergic drugs are still considered
“ﬁrst line” pharmacologic treatment for sialorrhea.
Unfortunately, on this date, no randomized trial comparing
the efﬁcacy of these different agents in ALS patients was
published. To our knowledge, only one double-blind com-
parative study has evaluated the sialorrhea treatment efﬁ-
cacy with transdermal scopolamine compared to placebo
in ALS; this highlighted a decrease in the mean daily
volume of saliva in patients treated with scopolamine,
however without a signiﬁcative difference in Visual
Analogue Scale.32
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Botulinum toxin
Comparing the results of the studies on Botulin toxin
treatment is difﬁcult, because there are several heteroge-
neity of toxin types, dosages, outcome measures and injec-
tion technique. One common objective measure in studies
using botulinum toxin B was weighing cotton wool balls
placed in the mouth before and after treatment. However,
this measure is inﬂuenced by a number of factors (cotton
wool ball position, duration of absorption assessment,
methodology). Despite these limitations, the strongest evi-
dence supports the use of botulinum toxin B injections for
the management of drooling among ALS patients reduces,
in signiﬁcant and persistent manner, the saliva production.
This is in agreement with the updated Practice Parameter
of The American Academy of Neurology.22 The anatomi-
cal location of the injection can be identiﬁed by either
anatomical markers, electromyography or ultrasound gui-
dance. The latter is a more precise procedure.33–35
However, in some reported cases, patients were main-
tained on anticholinergic medications making, it difﬁcult
to distinguish between the effects of botulinum toxin
injections from those of other medications. Side-effects
were reported in a third of patients.33,36–38 The most fre-
quent one was worsening of dysphagia and dysarthria.39,40
A number of issues related to botulinum B toxin are yet
to be determined.41 There is no consensus on which glands
should be injected and with how many units per dose (2.500
units?). There is limited information on how many sites
within each gland should be considered and whether ultra-
sound guidance is really signiﬁcantly more beneﬁcial.
Radiotherapy
Head and neck radiation therapy (RT) typically tries to spare
the parotid glands because it may reduce salivation and cause
dry mouth symptoms in cancer patients.42 Because of this
secondary effect, RT of the salivary gland could be an alter-
native and effective technique to reduce sialorrhea in ALS
patients: in a retrospective study, there was a good response in
65% of subjects. Different techniques and doses have been
reported in previous studies on radiotherapy and, for this
reason, there is no consensus on the type of radiation (elec-
tron-based therapy vs photon-based therapy) and on the opti-
mum total dose.43 It was obtained a positive effect on the
administration of 20 Gy in 5 fractions on the whole of the
submandibular gland and sparing the upper part of the parotid
gland. Similar beneﬁcial effects have been described by using
computed tomography to target a single parotid gland and
delivering a global dose of 15 Gy divided into 3 fractions.10
Single-dose radiotherapy (single fraction of 7.5 Gy) has also
been described as beneﬁcial in reducing excessive drooling in
ALS [60]. On the other hand, there are other suggestions
indicating that the delivery of a single dose of 8 Gy could be
as effective and safe compared to higher fractionated doses
and increasing the dose does not lead to additional
improvement.,41,43Electron-based therapy appears to be better
tolerated, more effective in the long term (persistent positive
effects 4–6 months after treatment) compared with photon-
based therapy.41,43 A recent review recommends dose-fractio-
nation schemes of 12 Gy in 2 fractions or 20 Gy in 4 fractions
with treatments twice a week.44 In addition, photon-based
therapy can determine acute collateral effects (oral pain and
mucositis during or immediately after irradiation) or delayed
local reaction (edema or xerostomia up to one month after
irradiation or oral pain three months after irradiation).45
Considering that life expectancy is reduced in ALS, the
probability to have radiation-induced malignancy after RT is
relatively low related to the course of the disease. Still, ALS
patients with supposed extended survival need to be
addressed at the time of radiation oncologist’s consultation,
particularly in patients with a slower course of ALS.46,47
In conclusion, a great number of ALS patients with
salivation problems respond well to therapeutic salivary
gland irradiation and the improvement may last for several
months. Neurologists should consider this treatment option
for select ALS patients.
Surgical options
The surgical treatment for sialorrhea is the last-choice
therapeutic option and it is suggested:
1. In case of persistent moderate sialorrhea not
responding to conservative treatments.
2. In severe sialorrhea cases in whom previous treat-
ment trials have failed or have had limited results
with conservative treatment.
3. In cases where compliance to conservative treat-
ments is limited due to cognitive impairment.
Neurectomy
The tympanic plexus nerve decreases the production of saliva.
Together with the tympanic cord, they may be cut, bilaterally
or unilaterally, alone or helped by other procedures as sub-
mandibular gland exeresis. The quantity of secretion from
submaxillary and sublingual glands is reduced by the
Garuti et al Dovepress
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neurectomy of the tympanic cord. Complications, like audi-
tory loss or decreased perception of taste in the ﬁrst two
sections of the tongue, can take place. Indeed, it is not sug-
gested to patients who already have hearing problems before
the therapy. Long-term results from isolated neurectomies are
not deﬁnitive.48
Surgical procedures on the salivary duct
and gland
Most known studies describing the surgical procedure to con-
trol excessive droolingwere performed on children affected by
cerebral palsy. The main procedure is made up by retroposi-
tioning the parotid ducts into the tonsillar fossa region along
with the bilateral submandibular gland resection. In these
patients, other effective variants of themain surgical procedure
(Wilkie’s procedure) have been shown:
1. relocation of the submandibular gland duct into the
tonsillar fossa;
2. ligation of the parotid ducts, along with the usual
submandibular gland resection;
3. deviation of both submandibular and parotid ducts
behind the anterior pillar of the soft palate;
4. bilateral submandibular duct relocation with or
without sublingual gland excision;
5. a combination of homolateral parotid duct ligation
and contralateral parotid duct repositioning;
6. ligation of both parotid and submandibular ducts
(four-duct ligation).
In 2009, Reed et al, published a metanalysis that showed how
bilateral submandibular duct rerouting, bilateral submandib-
ular gland excision with bilateral parotid duct rerouting and
bilateral submandibular gland excision with bilateral parotid
duct ligation are similarly effective.49 Although being poten-
tially less efﬁcient, four-duct ligation allows a safe, quick and
simple method that can help to control symptoms.50
In conclusion, although a surgical approach to sialor-
rhea is theoretically possible in other patients (cerebral
palsy children), there is no evidence as yet in patients
with ALS. Indeed, at this time this procedure is not
standardized and therefore not recommended in ALS
patients although there may be interested in the future
for severe cases in whom a deﬁnitive approach is
required.
Recommendations
1. The ﬁrst sialorrhea therapeutic approach in ALS is
made up by amitriptyline, oral or transdermal hyos-
cine, scopolamine, or sublingual atropine drops.51
2. Botulinum toxin injections into the parotid and/or
submandibular gland are tolerated and effective
when injected in patients with refractory
sialorrhoea.51
3. In ALS patients with consequent sialorrhoea, injec-
tions of botulinum into the parotid gland reduce
sialorrhoea and improves QOL up to four months,
with an efﬁcacy at four weeks from the injection.52
4. Avoiding direct injections of botulinum into salivary
ducts is suggested because associated with signiﬁ-
cant adverse effects.52
5. In the case of pharmacological treatment failure,
irradiation of salivary glands may be tried.51
6. Radiotherapy of salivary glands has shown its efﬁ-
cacy in reducing sialorrhoea at doses from 7 to 12.5
Gy up to six months.52
7. Surgical interventions are not recommended due to:
low life expectancy of patients, and inability to
tolerate surgical intervention. In selected cases, sur-
gery could represent an alternative treatment
because the advantages are no tachyphylaxis and
no repeated therapeutic sessions.53
8. Consider the duration of the treatment: There is
some evidence indicating that both botulinum and
radiotherapy are well tolerated, effective treatments
for persistent sialorrhea in patients with ALS and
that the duration of action is up to three months with
botulinum and six months with radiotherapy.52
9. Discuss with the patients the best options of
treatment.6
There are different approaches into treatment timing:
the EFNS guidelines start with amitriptyline, followed by
oral or transdermal hyoscine, or sublingual atropine drops,
botulinum toxin injections in utilized in refractory cases.
Irradiation is considered as an option after pharmacologi-
cal treatment failure.54 In for patients with cognitive
impairment, the NICE guidelines introduce glycopyrrolate
as a ﬁrst-line of treatment because of fewer central nervous
side effects.55
Dovepress Garuti et al
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Conclusion
Evidence from previous studies is limited and there are
still a number of open questions. How can we measure
sialorrhea in a reliable and reproducible way? How can
we measure the impact of this speciﬁc symptom on the
patients’ perception of life quality? How long shall the
treatment last?52 We should consider that there may be a
need to include measures which speciﬁcally address the
impact of drooling on quality of life, rather than hoping
to determine efﬁcacy measuring the impact on overall
QOL. In any case, quantitative and qualitative disorders
in salivary secretions are frequent in clinical practice
and sialorrhea is burdensome for patients and care-
givers. Currently, there are a number of drugs that may
be, at least partially, beneﬁcial, but side effects need to
be considered. In this respect, it is important that treat-
ment is tailored according to the severity and impact on
the patient’s quality of life, balancing side effects. We
believe that the stepwise structured approach described
may prove to be a useful tool to guide clinical practice
and better target treatment of sialorrhea in ALS
(Figure 2).
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